{"groups":[{"description":"Eligible participants with triple-class refractory multiple myeloma (TCR MM), who were B-cell maturation antigen (BCMA) naïve, who were enrolled between 2 February 2021 to 07 January 2022 and who were treated with elranatamab in study C1071003 were included.","id":"FG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR MM who were treated with standard of care (SOC) therapies in real world clinical practice setting, identified from COTA database were included. This arm served as external control arm.","id":"FG001","title":"RWD: COTA"},{"description":"Eligible participants with TCR MM who were treated with SOC therapies in real world clinical practice setting, identified from Flatiron Health database were included. This arm served as external control arm.","id":"FG002","title":"RWD: Flatiron Health"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"239"},{"groupId":"FG002","numSubjects":"152"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"239"},{"groupId":"FG002","numSubjects":"152"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This retrospective cohort study used participant level data from study C1071003 (NCT04649359), and external control arms identified from real world data (RWD) sources."}